Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer
Durairaj C, Ruiz-Garcia A, Gauthier ER, Huang X, Lu DR, Hoffman JT, Finn RS, Joy AA, Ettl J, Rugo HS, Zheng J, Wilner KD, Wang DD
Anticancer Drugs. 2018 Mar;29(3):271-280
CARDIONCOLOGY.ORG ABSTRACT:
The aim of this study was to assess the potential effects of palbociclib in combination with letrozole on QTc.
Palbociclib, when administered with letrozole at the recommended therapeutic dosing regimen, did not prolong the QT interval to a clinically relevant extent.
© All Rights Reserved
Image source: https://www.clearsynth.com/en/CST38566.html